Literature DB >> 11035431

Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations.

G Sanna1, M Piga, J W Terryberry, M T Peltz, S Giagheddu, L Satta, A Ahmed, A Cauli, C Montaldo, G Passiu, J B Peter, Y Shoenfeld, A Mathieu.   

Abstract

The aim of this study was to evaluate morphological and functional abnormalities by cerebral imaging in a series of systemic lupus erythematosus (SLE) patients with and without overt central nervous system (CNS) manifestations, and to detect possible relationships with clinical parameters and a large panel of autoantibodies, including those reactive against neurotypic and gliotypic antigens. 68 patients with SLE were investigated in a cross-sectional study which included clinical evaluation of symptoms, cerebral magnetic resonance imaging (MRI) and brain single photon emission tomography (SPECT) analysis, electroencephalography (EEG), and serological tests for antibodies directed against nuclear, cytoplasmic neuronal and glial cell-related antigens. The results of this study showed: (1) a significant positive association of (a) anti-glial fibrillary acidic protein (GFAP) serum antibodies with neuropsychiatric (NP) manifestations and (b) anti-serin proteinase 3 (anti-PR3/c-ANCA) serum antibodies with pathological cerebral SPECT; (2) the presence of significantly higher values of (a) SLICC organ damage index in patients with abnormal MRI and (b) SLAM activity index in patients with abnormal SPECT; and (3) the association of (a) abnormal MRI with nonactive NP manifestations and (b) combined abnormality of brain SPECT and MRI with the occurrence of overall overt NP manifestations and with those of the organic/major type. Neuropsychiatric manifestations, namely those of the organic/major type, appeared to be significantly associated to the presence of a serum antibody against GFAP, a gliotypic antigen. There was also evidence of an association between SPECT abnormality and the presence of anti-PR3 (c-ANCA). Furthermore, brain imaging by MRI and SPECT applied to SLE patients appears to express CNS involvement significantly related to specific categories of NP manifestations. The abnormalities detected by the two tests seem to be preferentially associated with different activity phases of the NP disorder or of the lupus disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035431     DOI: 10.1191/096120300678828695

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  36 in total

1.  Diagnosis and treatment of cerebral vasculitis.

Authors:  Peter Berlit
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

2.  Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions.

Authors:  Hae Woong Jeong; Minyoung Her; Jong Seok Bae; Seong-Kyu Kim; Sung Won Lee; Ho Kyun Kim; Dongyook Kim; Nayoung Park; Won Tae Chung; Sang Yeob Lee; Jung-Yoon Choe; In Joo Kim
Journal:  Rheumatol Int       Date:  2014-10-15       Impact factor: 2.631

3.  R-R interval variation and sympathetic skin response in systemic lupus erythematosus.

Authors:  Aslan Tekatas; Süleyman Serdar Koca; Demet Deniz Tekatas; Feyza Aksu; Yüce Dogru; Omer Nuri Pamuk
Journal:  Clin Rheumatol       Date:  2013-09-22       Impact factor: 2.980

Review 4.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

5.  Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; William M Brooks; Mario Kornfeld; Blaine L Hart; Arthur D Bankhurst; Carlos A Roldan
Journal:  Semin Arthritis Rheum       Date:  2009-10-31       Impact factor: 5.532

6.  Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus.

Authors:  Michelle Petri; Mohammad Naqibuddin; Kathryn A Carson; Daniel J Wallace; Michael H Weisman; Stephen L Holliday; Margaret Sampedro; Shalini Narayana; Peter T Fox; Crystal Franklin; Patricia A Padilla; Robin L Brey
Journal:  J Rheumatol       Date:  2008-09-15       Impact factor: 4.666

7.  Intracranial hypertension syndrome in systemic lupus erythematosus: clinical analysis and review of the literature.

Authors:  Zheng Xue; Xuezhen Wang; Fei Liu; Shaoxian Hu; Suiqiang Zhu; Suming Zhang; Bitao Bu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

Review 8.  Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus.

Authors:  Tony N Marion; Arnold E Postlethwaite
Journal:  Semin Immunopathol       Date:  2014-08-08       Impact factor: 9.623

9.  Classification criteria for neuropsychiatric systemic lupus erythematosus: do they need a discussion?

Authors:  S Monov; D Monova
Journal:  Hippokratia       Date:  2008-04       Impact factor: 0.471

10.  Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study.

Authors:  Yasuhiro Katsumata; Masayoshi Harigai; Yasushi Kawaguchi; Chikako Fukasawa; Makoto Soejima; Tokiko Kanno; Katsuji Nishimura; Takayuki Yamada; Hisashi Yamanaka; Masako Hara
Journal:  BMC Musculoskelet Disord       Date:  2010-01-23       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.